CR01663-2025

The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.

Medilines Distributors IncorporatedMEDIC

PSE Disclosure Form 17-3 - Request for Extension to File SEC Form 17-A References: SRC Rule 17, SEC Memorandum Circular No. 7 Series of 2008 and
Section 17.2 and 17.8 of the Revised Disclosure Rules

For the fiscal year ended Dec 31, 2024
Deadline of Submission of Annual Report Apr 15, 2025
Reason for requesting extension to submit Annual Report

Medilines Distributors Incorporated, (the “Company) would like to request for an extension of
the deadline to file its Annual Report under SEC Form 17-A for the calendar year ended
December 31, 2024.

The Company has yet to finalize the review of its financial statements and it does not expect
to complete such review by April 15, 2025, the original deadline of filing the Annual Report.
Since the non-financial portions of the Annual Report will be derived from the contents of the
audited financial statements, the Company is constrained to defer the filling of its entire SEC
Form 17-A to a later date.

The Company undertakes to submit the report within fifteen (15) days after the original April
15, 2025 deadline or upon submission of the report to the Securities and Exchange
Commission, whichever is earlier.

Other Relevant Information

-

The Company undertakes to submit the report within fifteen (15) calendar days after the prescribed deadline or upon submission of the report to the Securities and Exchange Commission, whichever is earlier. The Company understands that failure to comply with the undertaking may result to the imposition of applicable penalty/ies and/or sanction/s.

Filed on behalf by:
Name Myra De Asis
Designation Chief Financial Officer